A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS The Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity. The Company believes that the mechanism by which LB-100 affects cancer cell growth is different from cancer agents currently approved for clinical use.
| Metric | TTM | FY2015 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 0 | 0 | 0 | 0 |
| Net Income | -4.1M | -2.9M | -1.4M | -3.6M | -2.1M | -880K |
| EPS | $-1.19 | $-0.60 | $-0.30 | $-0.90 | $-0.60 | $-0.30 |
| Free Cash Flow | 0 | -2.2M | -1.2M | -1.2M | -1.4M | -936K |
| ROIC | -56.7% | -669.4% | -459.7% | -111.5% | -1867.8% | -50.7% |
| Gross Margin | - | 0.0% | - | - | - | - |
| Debt/Equity | 0.00 | 0.91 | 1.36 | 0.18 | 4.44 | 0.11 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -3.9M | -2.6M | -1.4M | -2.1M | -1.9M | -882K |
| Operating Margin | 0.0% | 0.0% | - | - | - | - |
| ROE | -84.2% | -913.8% | -159.1% | -239.9% | -227.8% | -50.7% |
| Shares Outstanding | 6M | 5M | 5M | 4M | 3M | 3M |
| Metric | 2010 | 2011 | 2012 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 0 | 0 | 0 | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | 0.0% | N/A |
| R&D | 446K | 1.3M | 1.0M | 880K | 2.1M | 238K |
| SG&A | 436K | 533K | 1.1M | 495K | 754K | 5.0M |
| EBIT | -882K | -1.9M | -2.1M | -1.4M | -2.6M | -3.9M |
| Op. Margin | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Net Income | -880K | -2.1M | -3.6M | -1.4M | -2.9M | -4.1M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -50.7% | N/M | -111.5% | N/M | N/M | -56.7% |
| ROE | -50.7% | -227.8% | -239.9% | -159.1% | -913.8% | -84.2% |
| ROA | -45.6% | -175.2% | -204.2% | -119.0% | -477.3% | -76.1% |
| Cash Flow | ||||||
| Op. Cash Flow | -936K | -1.4M | -1.2M | -1.2M | -2.2M | -2.6M |
| Free Cash Flow | -936K | -1.4M | -1.2M | -1.2M | -2.2M | 0 |
| Owner Earnings | -1.1M | -1.6M | -1.2M | -1.2M | -2.7M | -3.8M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 161K | 205K | N/A | N/A | 550K | 1.2M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -5.8M |
| Cash & Equiv. | 119K | 14K | 1.7M | 475K | 25K | 5.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.11 | 4.44 | 0.18 | 1.36 | 0.91 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | 0.0 | 0.0 |
| Equity | 1.7M | 79K | 1.5M | 236K | 312K | 4.9M |
| Total Assets | 1.9M | 430K | 1.8M | 558K | 598K | 5.4M |
| Total Liabilities | 195K | 351K | 261K | 322K | 286K | 236K |
| Intangibles | N/A | N/A | N/A | N/A | 0 | 0 |
| Retained Earnings | N/A | N/A | N/A | N/A | -19M | -56M |
| Working Capital | 1.7M | 79K | 1.5M | 236K | 312K | 4.9M |
| Current Assets | 1.9M | 430K | 1.8M | 558K | 598K | 5.4M |
| Current Liabilities | 195K | 351K | 261K | 322K | 286K | 521K |
| Per Share Data | ||||||
| EPS | -0.30 | -0.60 | -0.90 | -0.30 | -0.60 | -1.19 |
| Owner EPS | -0.37 | -0.45 | -0.30 | -0.26 | -0.57 | -0.67 |
| Book Value | 0.59 | 0.02 | 0.38 | 0.05 | 0.07 | 0.86 |
| Cash Flow/Share | -0.32 | -0.39 | -0.30 | -0.26 | -0.46 | -0.72 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 2.9M | 3.4M | 4.0M | 4.6M | 4.8M | 5.7M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -2.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 35.5 | N/A | 40.0 | 151.3 | N/A | 3.4 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -1.5% | -1.3% | -2.0% | -3.3% | N/A | N/A |
| Market Cap | 62M | 103M | 60M | 36M | 0 | 17M |
| Avg. Price | 25.70 | 42.73 | 36.71 | 17.24 | 0.00 | 2.93 |
| Year-End Price | 21.00 | 30.00 | 15.00 | 7.80 | 0.00 | 2.93 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) has a 5-year average return on invested capital (ROIC) of -81.1%. This is below average and may indicate limited pricing power.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) has a market capitalization of $17M. It is classified as a small-cap stock.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) does not currently pay a regular dividend.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) has a debt-to-equity ratio of 0.91. This indicates moderate leverage.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) reported earnings per share (EPS) of $-0.60 in its most recent fiscal year.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) has a return on equity (ROE) of -913.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) has a book value per share of $0.07, based on its most recent annual SEC filing.